ClinicalTrials.gg
Enrolling by invitationNCT05934617TRAJLUNGUpdated May 16, 2024

Trajectories of FEV1 After Lung Transplantation

An observational study in Lung Transplant Failure and Rejection and Chronic Lung Allograft Dysfunction, sponsored by Paris Translational Research Center for Organ Transplantation. Enrolling by invitation at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Paris Translational Research Center for Organ Transplantation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Study summary

For individuals with ESLD, lung transplantation is the best, or only treatment option with increased pulmonary function and quality of life. The forced expiratory volume in one second (FEV1) is the standard to monitor the lung function after transplantation. The goal of this study is to identify and validate the FEV1 trajectories after lung transplantation, as well as their determinants and outcomes, using an international cohort of lung recipients.

Read the detailed description

Chronic lung diseases affect about 500 million individuals and are the third leading cause of death worldwide, accounting for 7% of all mortality. They drive the growing number of individuals with end stage lung disease (ESLD), a public health issue with socioeconomic consequences.

For individuals with ESLD, lung transplantation is the best, or only treatment option with increased pulmonary function and quality of life. Lung recipients remain however particularly at risk, with a median patient survival of around five years, which is much lower than other organ recipients, such as kidney, heart or liver recipients. Adequate monitoring of the lung recipient is therefore crucial to optimize the allograft longevity.

The forced expiratory volume in one second (FEV1) is the standard to monitor the lung function after transplantation, and is used to evaluate the stage and severity of lung allograft diseases. However, according to a literature review we performed, the very few studies that have investigated the FEV1 evolution, and its relationship with outcomes such as death or chronic lung allograft dysfunction, were commonly based on cohort with insufficient data variety and completeness. Importantly, these studies lacked external validation, multidimensional approach, and none has attempted to identify the main profiles of FEV1 trajectories and their associated parameters. As such, the determinants and long-term outcomes of FEV1 trajectories are still poorly understood.

A multidimensional, trajectory-based approach may help unveil clinically relevant organ function profiles among lung recipients. Indeed, several studies have shown the potential existence of underlying trajectories of transplanted organs' function and diseases, and their associations with outcomes and relevance for patient management, such as in kidney or heart transplantation. These studies used a unsupervised approach, which permitted to erase any preconceived clinical ideas. Overall, this approach has shown its value in several medical specialties, in particular in image analysis, oncology, or cardiology.

Therefore, the goal of this study was to identify and validate the FEV1 trajectories after lung transplantation, as well as their determinants and outcomes, using an international cohort of lung recipients, with a protocol-based collection of FEV1 repeated assessments and clinical, biological, histological and immunological data.

02

Conditions studied

  • Lung Transplant Failure and Rejection
  • Chronic Lung Allograft Dysfunction

Keywords

  • Lung trajectories
  • Unsupervised analysis
  • Determinants of FEV1 trajectories
03

In context

Lead sponsor

Paris Translational Research Center for Organ Transplantation is the lead sponsor of 31 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who received a bilateral lung transplantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Double lung transplant recipients
  • Age 18 years or older at the time of transplant
  • Transplant between January 1, 2010 and December 31, 2020
  • At least 2 PFTs available for analysis

Exclusion criteria

Exclusion Criteria:

  • Did not consent to clinical data use for research purposes
  • Multi-organ transplant
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Foch hospital

    Lung recipients from Foch hospital, Suresnes, France

  • Bichat hospital

    Lung recipients from Bichat hospital, Paris, France

  • Nantes hospital

    Lung recipients from Nantes hospital, Nantes, France

  • San Antonio center

    Lung recipients from Pulmonary hypertension center, San Antonio, Texas, US

  • Marie-Lannelongue hospital

    Lung recipients from Marie-Lannelongue hospital, Le Plessis-Robinson, France

  • Bordeaux hospital

    Lung recipients from Bordeaux hospital, Nantes, France

  • Marseille hospital

    Lung recipients from Marseille hospital, Marseille, France

  • Toulouse hospital

    Lung recipients from Toulouse hospital, Toulouse, France

  • Strasbourg hospital

    Lung recipients from Strasbourg hospital, Strasbourg, France

  • Grenoble hospital

    Lung recipients from Grenoble hospital, Grenoble, France

  • Cochin hospital

    Lung recipients from Strasbourg hospital, Paris, France

  • Hospital center Mayenne North

    Lung recipients from Hospital center Mayenne North, Mayenne, France

06

What researchers measure

Primary outcomes

  1. FEV1 trajectories

    FEV1 trajectories of the lung recipient

    Time frame: Up to 10 years after lung transplantation

Secondary outcomes

  1. Patient death

    Patient death after lung transplantation

    Time frame: Up to 10 years after lung transplantation

  2. Allograft failure

    Allograft failure after lung transplantation

    Time frame: Up to 10 years after lung transplantation

  3. Chronic lung allograft dysfunction

    CLAD after lung transplantation

    Time frame: Up to 10 years after lung transplantation

07

Study locations

1 site
08

References and documents

Publications

  • GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020 Jun;8(6):585-596. doi: 10.1016/S2213-2600(20)30105-3. PubMed 32526187 ↗
  • Li X, Cao X, Guo M, Xie M, Liu X. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020 Feb 19;368:m234. doi: 10.1136/bmj.m234. Erratum In: BMJ. 2020 Aug 6;370:m3150. doi: 10.1136/bmj.m3150. PubMed 32075787 ↗
  • Brakema EA, Tabyshova A, van der Kleij RMJJ, Sooronbaev T, Lionis C, Anastasaki M, An PL, Nguyen LT, Kirenga B, Walusimbi S, Postma MJ, Chavannes NH, van Boven JFM; FRESH AIR collaborators. The socioeconomic burden of chronic lung disease in low-resource settings across the globe - an observational FRESH AIR study. Respir Res. 2019 Dec 21;20(1):291. doi: 10.1186/s12931-019-1255-z. PubMed 31864411 ↗
  • Perch M, Hayes D Jr, Cherikh WS, Zuckermann A, Harhay MO, Hsich E, Potena L, Sadavarte A, Lindblad K, Singh TP, Stehlik J; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease. J Heart Lung Transplant. 2022 Oct;41(10):1335-1347. doi: 10.1016/j.healun.2022.08.007. Epub 2022 Aug 20. No abstract available. PubMed 36050206 ↗

Individual participant data

Plan to share: Yes — Deidentified data may be shared for research purpose upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication

Access criteria: Via email to the corresponding author

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jan 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Jul 7, 2023
StartActual
Jan 1, 2020
Primary completionActual
Jan 1, 2021
CompletionEst.
Jul 1, 2024
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05934617
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Jan 1, 2020
Primary completion
Jan 1, 2021
Completion
Jul 1, 2024 (estimated)
Last update
May 16, 2024

Study contacts

Antoine Roux, MD, PhD
principal investigator · Foch hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion